ARWR

Arrowhead Pharmaceuticals' stock has increased significantly in the past six months, with a 98.70% increase and a 488.3% surge over the past year. On November 25, 2025, the U.S. FDA approved REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome (FCS). On February 5, 2026, the company reported Q1 2026 earnings, with shares declining 0.2% the day after the announcement. On April 24, 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use (EMA CHMP) adopted a positive opinion recommending approval of REDEMPLO in Europe. On May 1, 2026, Arrowhead announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals for ARO-PNPLA3, including a $25 million upfront payment and potential milestones up to $975 million. On May 7, 2026, the company reported Q2 2026 earnings, with shares declining 0.78% in aftermarket trading despite beating EPS and revenue forecasts, highlighting accelerating commercial uptake for REDEMPLO, with over 400 prescriptions since launch and a 40% increase in the four weeks leading up to May 7, 2026. Topline results from Phase 3 SHASTA-3 and SHASTA-4 studies for plozasiran in severe hypertriglyceridemia (SHTG) are expected in Q3 2026.